Marine Antineoplastic templates: Clinical trials (I-III) and Motifs Carried via Antibodies to Target Specific Cancerous Tissues.
Abdel-Nasser El-Shorbagi1*
, Sachin Chaudhary1, Anurag Chaudhary2, Garima Agarwal2, Prabhash Nath Tripathi2, Shweta Dumoga2, Alaa Ali Aljarad1, Esraa Omer1, Fatma Mahmoud1, Ramesh Kumar Gupta3 and Mahmoud Hamed Mohamed41Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
2Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, NH-58, Baghpat Road Crossing, Bypass Road, Meerut, India.
3Department of Pharmacology, Hygia Institute of Pharmaceutical Education and Research Lucknow, Uttar Pradesh, India.
4Department of Pharmacognosy, College of Clinical Pharmacy, Albaha University, Saudi Arabia.
Corresponding Author E-mail: aelshorbagi@sharjah.ac.ae
Abstract: Aquatic environment is one of the important sources of active agents that own diverse biological properties. Metabolites from these sources are considered as alternate source to meet the mandate for effective medicines. Despite notable developments in cancer managing and/or treatment in the past years, there remains a vital requirement for innovative agents and/or innovating approaches to treat resistant and solid tumours. However, in the recent era there are new technological innovations in the elucidation of the structures, the semi-synthetic and synthetic approaches of the new antineoplastic compounds. Biological assays enable isolation and clinical evaluation of numerous scaffolds from the marine environment. This review gives a general summary of some anti-cancer agents with a brief description of their mechanisms of action. It sheds a view to the approved drugs, the potent scaffolds that newly modulated as antibody-drug conjugates, and the drug-candidates under clinical phases (I-III) with their status.
Keywords: Antibody Drug Conjugate; Anticancer Agents; Clinical Phase; Marine Drugs; Metabolites Back to TOC